MedTrace Logo

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

NCT00040378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4246

Last updated 2018-03-14

No results posted yet for this study

Summary

The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

alphatocopherol

400 IU daily

DRUG

Selenium

200mcg daily

DRUG

Placebo replacement for vitamin E

1 placebo pill daily

DRUG

Placebo replacement for Selenium

1 placebo pill daily

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Frederick Schmitt

    lead OTHER

Principal Investigators

  • Frederick Schmitt, PhD · Sanders-Brown Center on Aging

  • Richard Kryscio, PhD · Sanders-Brown Center on Aging

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2014-01-31
Completion
2016-08-31

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040378 on ClinicalTrials.gov